Pharmacologic properties of (-)-3PPP (preclamol) in man

C. A. Tamminga, N. G. Cascella, R. A. Lahti, M. Lindberg, A. Carlsson

Research output: Contribution to journalArticlepeer-review

39 Scopus citations


The dopamine (DA) autoreceptor agonist (-)-3PPP (preclamol) was tested in male schizophrenic volunteers for safety. The drug was administered intramuscularly in a single rising dose design, crossed with a similar "rising dose" placebo period; all evaluations and raters were blind to drug or placebo administration. Pharmacokinetic, endocrine, safety, and mental status outcome measures were completed before and after each single dose of drug or placebo. Pharmacokinetic analysis showed blood levels between 200-500 pmoles/ml after the intramuscular drug doses of 30-40 mg. Drug half life is 2-2.5 hrs. Growth hormone (GH) levels were elevated in a linear fashion to the 30 mg dose; whereafter, the drug failed to affect GH at all. All safety evaluations were negative, including any untoward effects on the major organ systems. After single dose drug administration, evidence of antipsychotic action occurred in two of the four subjects. This study suggests that (-)-3PPP/preclamol is a safe drug for study in the treatment of schizophrenia and may have antipsychotic efficacy.

Original languageEnglish (US)
Pages (from-to)165-175
Number of pages11
JournalJournal of Neural Transmission
Issue number3
StatePublished - Oct 1992
Externally publishedYes


  • (-)-3PPP
  • antipsychotic
  • autoreceptor
  • Partial dopamine agonist
  • schizophrenia

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Pharmacologic properties of (-)-3PPP (preclamol) in man'. Together they form a unique fingerprint.

Cite this